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AbstrACt
Objective To address uncertainties prior to conducting a 
fully powered randomised controlled trial of Morita Therapy 
plus treatment as usual (TAU) versus TAU alone, or to 
determine that such a trial is not appropriate and/or feasible.
Design Pilot parallel group randomised controlled 
feasibility trial.
setting and participants Participants aged ≥18 years 
with Diagnostic and Statistical Manual of Mental Disorders 
(DSM)-IV major depressive disorder, with or without DSM-
IV anxiety disorder(s), recruited from general practice 
record searches in Devon, UK.
Interventions We randomised participants on a 1:1 basis 
stratified by symptom severity, concealing allocation using 
a secure independent web-based system, to receive TAU 
(control) or 8–12 sessions of Morita Therapy, a Japanese 
psychological therapy, plus TAU (intervention).
Outcomes Rates of recruitment, retention and treatment 
adherence; variance and estimated between-group 
differences in follow-up scores (on the Patient Health 
Questionnaire 9 (PHQ-9) (depressive symptoms); 
Generalised Anxiety Disorder Questionnaire 7 (anxiety 
symptoms); Short Form 36 Health Survey Questionnaire/
Work and Social Adjustment Scale (quality of life); Morita 
Attitudinal Scale for Arugamama (attitudes)) and their 
correlation with baseline scores.
results We recruited 68 participants, 5.1% (95% CI 3.4% 
to 6.6%) of those invited (34 control; 34 intervention); 64/68 
(94%; 95% CI 88.3% to 99.7%) provided 4-month follow-up 
data. Participants had a mean age of 49 years and mean 
PHQ-9 score of 16.8; 61% were female. Twenty-four of 34 
(70.6%) adhered to the minimum treatment dose. The follow-
up PHQ-9 (future primary outcome measure) pooled SD was 
6.4 (95% CI 5.5 to 7.8); the magnitude of correlation between 
baseline and follow-up PHQ-9 scores was 0.42 (95% CI 0.19 
to 0.61). Of the participants, 66.7% and 30.0% recovered in 
the intervention and control groups, respectively; 66.7% and 
13.3% responded to treatment in the intervention and control 
groups, respectively.
Conclusions A large-scale trial of Morita Therapy would 
require 133 participants per group and is feasible with minor 
modifications to the pilot trial protocol. Morita Therapy shows 
promise in treating depression and may provide patients with 
a distinct alternative to current treatments.
trial registration number ISRCTN17544090; Pre-results.
IntrODuCtIOn AnD ObjeCtIves 
Globally, depression is the leading cause of 
disability, affecting 350 million people world-
wide.1 In the UK, depression has a lifetime prev-
alence of 16.2%.2 For individuals, depression 
is often chronic and recurrent, and rates of 
comorbidity and risk for suicide are high.2–5 
Furthermore, the comorbidity between depres-
sion and anxiety disorders, such as generalised 
anxiety disorder (GAD), makes a strong contri-
bution to the total disability attributed to 
mental disorders.6–8 Overall, the cost of depres-
sion and anxiety in the UK is significant at an 
annual rate of £17 billion in lost output and 
direct healthcare costs.9 
Medication and cognitive behavioural 
therapy (CBT) have the strongest 
evidence base for treating depression, 
each being recommended by the National 
Institute for Health and Care Excellence 
(NICE).10 However, many people are resis-
tant to such interventions.11 Indeed, current 
treatments appear to have had little impact 
on the prevalence of common mental disor-
ders in the UK, and depression remains a 
chronic disorder despite the available inter-
ventions.6 12 Recovery (defined as Patient 
Health Questionnaire 9 (PHQ-9)13 score <10) 
is reached by fewer than 50% of patients who 
complete a NICE recommended psycholog-
ical therapy within the ‘Improving Access 
to Psychological Therapies’ service, thereby 
increasing patients’ risk of future relapses 
and the maintenance of chronic and recur-
ring problems.14–16 Similarly, studies suggest 
that between a third and half of depressed 
patients treated with psychotherapy or antide-
pressant medication do not respond to treat-
ment (typically defined as a 50% reduction in 
strengths and limitations of this study
 ► This is the first randomised controlled trial of 
Morita Therapy for depression in English-speaking 
countries.
 ► Our pilot trial used mixed methods to address the 
procedural, methodological and clinical uncertain-
ties associated with a large-scale trial.
 ► Criteria for success were specified a priori.
 ► The patients, clinicians and researchers were not 
blinded to group allocation, although self-report 
measures were used to reduce detection bias.
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symptoms).17–23 Thus, there is scope to develop and test 
new potentially effective treatments for depression.
Morita Therapy is a Japanese psychotherapy devel-
oped by Dr Shōma Morita in 1919, and informed by Zen 
Buddhist principles.24 25 It is a holistic approach aiming 
to improve everyday functioning rather than targeting 
specific symptoms.26 Through conceptualising unpleasant 
emotions as part of the natural ecology of human expe-
rience, Morita Therapy seeks to reorientate patients in 
the natural world and potentiate their natural healing 
capacity. Morita therapists thus help patients to move 
away from symptom preoccupation and combat, which 
are considered to exacerbate symptoms and interfere 
with this natural recovery process.27 By helping patients 
to accept symptoms as natural phenomena which ebb 
and flow as a matter of course, Morita Therapy is in sharp 
contrast to the focus of established Western approaches 
on symptom reduction and control.28 In Morita Therapy, 
patients are taught to live with, rather than be without, 
their symptoms.
While other psychological therapies (such as Accep-
tance and Commitment Therapy29) also foster patients’ 
acceptance of symptoms, through Morita’s four experi-
ential stages of rest and increasing action-taking, accep-
tance has a uniquely active, spontaneous and paradoxical 
quality: it cannot be brought about by deliberate cogni-
tive reappraisal or meditative exercises (as per other 
approaches), but only through everyday behavioural 
experience.26 30 31 Indeed, according to Morita’s unique 
method of shifting patients’ attention away from self-re-
flection and immersing them in their environments, any 
efforts to consciously accept symptoms are considered 
counterproductive: maintaining focus on and there-
fore exacerbating symptoms.26 31 Thus, Morita Therapy 
is a unique psychotherapy with the potential to provide 
patients in the UK with a distinct and meaningful alterna-
tive to current treatment options.
Originally developed as an inpatient treatment for 
psychological problems similar to GAD, Morita Therapy 
is now applied to a wider range of conditions, including 
depression, and is considered a potentially pan-diagnostic 
approach given the absence of symptom focus.26 The 
approach is practised in Japan and applied to a limited 
degree in countries including Australia, China, North 
America, Russia and Rwanda.26 Initial evidence for the 
efficacy of Morita Therapy is largely based on case studies, 
predominantly conducted in Japan32 (Minami, M. 2011). 
A limited number of randomised controlled trials (RCTs) 
in China and the USA provide mixed evidence for the 
effectiveness of inpatient Morita Therapy for postschizo-
phrenic depression33 and inpatient/outpatient Morita 
Therapy for anxiety.34–38 However, to our knowledge, 
outpatient Morita Therapy for depression has not been 
tested using a randomised controlled design. Further-
more, no RCTs of any form of Morita Therapy for depres-
sion have been undertaken in English-speaking countries, 
and Morita Therapy is untested within the UK. Although 
a fully powered RCT is clearly required to establish the 
effectiveness of Morita Therapy, given the novelty of 
Morita Therapy in the UK a number of clinical, meth-
odological and procedural uncertainties39 prevented us 
from immediately undertaking such a trial.
Here, we report the results of a pilot RCT, comprising 
part of a mixed-methods programme of research 
undertaken to prepare for the design and conduct of a 
fully powered RCT of outpatient Morita Therapy plus 
treatment as usual (TAU) versus TAU alone for the treat-
ment of depression, or to determine that such a trial is not 
appropriate and/or feasible. Our pilot RCT was designed 
to address the uncertainties associated with conducting 
a definitive trial by gathering information on: (1) Likely 
rates of recruitment, retention and treatment adherence. 
(2) Variance in participant outcomes and how these 
correlate with baseline scores, in order to inform future 
sample size calculations. It follows on from a programme 
of work conducted with patients and therapists to develop 
our Morita Therapy clinical protocol.40 Findings from 
qualitative and mixed-methods work undertaken along-
side the trial, to explore the acceptability of Morita 
Therapy and how this relates to treatment adherence, are 
reported elsewhere.
research questions
1. What proportion of participants approached to take 
part in a trial of Morita Therapy for depression will 
agree to do so?
2. What proportion of participants who agree to take part 
in the trial will remain in the trial at 4-month follow-up?
3. What proportion of participants who agree to take part 
in Morita Therapy will adhere to a predefined per-pro-
tocol dose of Morita Therapy?
4. What is the variance in participant outcomes (depres-
sive symptoms; anxiety symptoms; quality of life; atti-
tudes towards symptoms) following Morita Therapy 
plus TAU and TAU alone, and how do they correlate 
with participants’ baseline scores?
5. What are the estimated between-group differences 
(and 95% CIs) in participant outcomes (depressive 
symptoms; anxiety symptoms; quality of life; attitudes 
towards symptoms) following Morita Therapy plus 
TAU and TAU alone?
MethODs
trial design
The Morita Trial was a mixed-methods feasibility study 
encompassing a pilot trial and embedded qualitative 
interviews. The trial, reported here, used a parallel group 
randomised controlled design.
Participants
We recruited people aged ≥18 years with Diagnostic and 
Statistical Manual of Mental Disorders (DSM-IV)41 Major 
Depressive Disorder, with or without DSM-IV anxiety 
disorder(s), assessed using standard clinical interview 
(Structured Clinical Interview for DSM-IV-TR (text revi-
sion) Axis Disorders, Clinical Trials Version42 (SCID)). 
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We excluded people who were cognitively impaired, had 
bipolar disorder or psychosis/psychotic symptoms, were 
substance-dependent, were currently in receipt of psycho-
logical therapy, and those whose risk of suicide was suffi-
ciently acute to demand immediate management by a 
specialist mental health crisis team.
We recruited participants through record searches at 
eight general practices in Devon, UK, to identify poten-
tial participants from depression read codes. Practice staff 
contacted potentially eligible patients to seek permission 
for researcher contact. Advertisements were also placed 
on the websites of the University of Exeter Medical School 
and Mood Disorders Centre (MDC) Accessing Evidence-
Based Psychological Therapies (AccEPT) Clinic; leaflets 
and flyers were placed in the waiting rooms of consenting 
Devon general practices; an email invitation was circu-
lated to former MDC participants who had consented to 
such contact. People who responded to these invitations/
advertisements were interviewed by the study team who 
provided detailed information on the study, assessed eligi-
bility and took informed written consent. The protocol 
has been published previously43 (see online supplemen-
tary file 1).
Interventions
Morita Therapy plus TAU
Participants allocated to the intervention group were 
asked not to engage in other formal courses of psycholog-
ical therapy during the course of their treatment. Other-
wise, they were free to access any other usual care and 
medication in liaison with their GP.
Morita Therapy consisted of 8–12 1 hour face-to-face 
weekly sessions delivered at the University of Exeter’s 
MDC AccEPT clinic (http://www. exeter. ac. uk/ mood-
disorders/ acceptclinic/) by two professionally accred-
ited research therapists experienced in the delivery of 
psychological interventions, including experimental 
treatments. Therapists were trained in Morita Therapy 
over 6 months. Training included background reading, 
attending presentations, involvement in the develop-
ment of the UK Morita Therapy outpatient protocol,40 
and practical training led by the second author (DAR), 
a clinically qualified academic with 10 years member-
ship of the Japanese Society for Morita Therapy. Prac-
tical training was experiential: role plays, diary examples, 
additional reading and peer support as per a tailored 
therapist training programme developed by the study 
team.40
Therapists followed the UK Morita Therapy outpatient 
protocol developed by the study team.40 DAR provided 
fortnightly supervision of cases together with advice 
and support. A qualitative checklist highlighting the key 
components of Morita Therapy, and key discussions to be 
held in facilitating patients’ engagement with the treat-
ment phases, was used as an aide memoir to structure 
supervision discussions and the assessment of fidelity. 
With the patient’s consent, all therapy sessions were 
audio-recorded for use in supervision.
During therapy, patients progressed through Morita 
Therapy’s four phases of rest and increasing action-taking 
in order to address fatigue, expand peripheral attention 
and move from a mood-oriented to purpose-oriented and 
action-based lifestyle. Therapists aided patients in reap-
praising their symptoms as part of the natural ecology 
of human experience; recognising the vicious cycle 
of symptom aggravation created by fixation on symp-
toms, contradictions between the ‘real’ and ‘ideal’, and 
attempts to fight or control otherwise inevitable emotions; 
and moving from a position of preoccupation with symp-
toms to acceptance of spontaneous affective experiences. 
Therapists continually reinforced the patient’s shift from 
self-reflection towards a focus on constructive action 
and the external environment. Patients completed daily 
diaries in which therapists wrote comments to increase 
communication and the opportunity for therapeutic 
reinforcement.
TAU alone
For the control group, no intervention (nor ‘waiting-list’ 
option) was offered by the study team. No specific recom-
mendation or requirement to alter the usual treatment 
received by depressed patients in the UK was made, and 
no restrictions were placed on the treatment options 
available to these participants. General practitioners 
(GPs) were free to treat and refer participants as would be 
their normal practice and participants were free to access 
any other care and services, including formal courses of 
psychological therapy such as CBT.
All participants, irrespective of their allocation, were 
free to choose whether or not to take antidepressant 
medication. For all participants, we informed their GP of 
their participation in the study and group allocation.
Outcomes
We collected demographic data including SCID diag-
noses at baseline assessment. We collected the following 
self-reported data at baseline and 4 months post-base-
line: severity of depressive symptoms (PHQ-9); severity 
of generalised anxiety symptoms (GAD Questionnaire 7 
(GAD-7)44); quality of life (Short Form 36 Health Survey 
Questionnaire (SF-36)45 and Work and Social Adjustment 
Scale (WSAS)46). We measured participants’ attitudes 
towards themselves and their symptoms using a question-
naire developed for Morita Therapy specific outcomes 
(Morita Attitudinal Scale for Arugamama (MASA)47).
We collected data on the flow of participants through 
the trial. For Morita Therapy participants, therapists also 
informed the study researchers of the number of therapy 
sessions attended and reason for ending treatment.
Trial success criteria
We defined criteria which should be met in order to 
determine if a fully powered trial would be feasible or 
not.39 43 These were:
1. Participant recruitment and retention: we can re-
cruit and retain sufficient participants to populate 
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a fully powered trial, that is, at a recruitment rate of 
12% of those invited and an attrition rate no higher 
than 20% of those randomised, in line with other UK 
National Institute for Health Research (NIHR) mental 
health trials.22 48
2. Participants will engage with and adhere to Morita 
Therapy at a rate on a par with other UK NIHR men-
tal health trials,22 that is, at least 65% of participants 
allocated to Morita Therapy attend the per-protocol 
minimum of at least 5 sessions out of a maximum of 
12 available sessions.
In terms of decision making against these criteria, 
should we have fallen below any of these rates in our pilot 
trial we would consider whether protocol modification 
or close monitoring during a fully powered RCT would 
address any failure to meet these criteria, or decide that a 
fully powered trial would not be feasible.39
sample size
A conventional power calculation is inappropriate for the 
purpose of a pilot trial.39 However, informed by our criteria 
above and guidance on using pilot studies to reliably esti-
mate variance for participant outcomes,39 49 we aimed to 
invite 570 potential participants, recruit 72 participants 
and follow up 60 participants (30 in each arm). These 
figures were sufficient to estimate (1) Participation rates 
(as percentage of subjects invited) of 10% with a margin 
of error of ±2.46%, 12% with a margin of error of ±2.67% 
or 15% with a margin of error of ±2.93%, based on 95% 
CIs. (2) Follow-up rates (as percentage of participants 
randomised) of 80% with a margin of error of ±9.24% or 
85% with a margin of error of ±8.25%, based on 95% CIs. 
(3) The SD of continuous outcomes to within 22% of 
their true value based on the upper limit of the 95% CI. 
(4) A Pearson’s correlation coefficient between baseline 
and follow-up scores with a margin of error of ±0.1 if the 
true correlation is 0.8, ±0.14 if the true correlation is 0.7 
or ±0.17 if the true correlation is 0.6.
randomisation
We randomised participants in a 1:1 ratio to the inter-
vention or control arm using a computer-generated 
random allocation sequence at the Exeter Clinical Trials 
Unit (ExeCTU). We stratified randomisation according 
to participants’ symptom severity on PHQ-9 and mini-
mised allocation to balance the stratification variable 
across the two arms. To ensure allocation concealment, 
we randomised using an externally administered, pass-
word-protected randomisation website independently 
developed and maintained by ExeCTU. Allocation 
occurred on completion of eligible participants’ baseline 
assessment. Subsequently, the study researchers informed 
the participant and their GP, via a standard letter, of the 
outcome and, for those randomised to the intervention 
group, passed participant details to the clinic to arrange 
treatment.
It was not possible to blind participants or clinicians to 
group allocation due to the nature of the intervention. 
The study researchers were not blinded to group allo-
cation due to resource limitations. However, baseline 
and follow-up data were self-reported and all research 
measures were applied equally to both groups to reduce 
potential detection bias.
statistical methods
We undertook all analyses on an intention-to-treat basis 
and did not impute missing data. We applied pairwise 
deletion to each measure in order to maximise the 
data available. Where a questionnaire item was missing 
(which occurred only at follow-up), pairwise deletion was 
applied to that follow-up measure for that participant. 
We reported recruitment, retention, treatment adher-
ence and baseline characteristics using descriptive statis-
tics: means and SDs for continuous variables; numbers 
and percentages for categorical variables. We reported 
the SDs of the outcome measures (all continuous) with 
95% CI for each trial arm at baseline and 4 months. We 
estimated the correlations between participants’ scores 
on these measures at baseline and 4 months to inform the 
sample size calculation for a fully powered trial. Although 
insufficiently powered to make inferential statements or 
calculate P values, we reported the observed differences 
between the intervention and control groups on the 
mean changes in these measures (with 95% CI), as well as 
proportions of participants recovering (follow-up PHQ-9 
and GAD-7 scores<1013 44) and responding to treatment 
(≥50% reduction in PHQ-9 and GAD-7 scores from base-
line to follow-up) in each trial arm.
Patient and public involvement
The Morita Trial follows on from an iterative programme 
of work conducted to develop our Morita Therapy clin-
ical protocol, whereby we optimised Morita Therapy 
according to the views of potential patients and ther-
apists.40 The patient materials were developed on the 
basis of consultation with a public and patient involve-
ment (PPI) expert and similar materials used in other 
mental health trials which had received feedback from 
PPI groups (eg, PenPIG http:// clahrc- peninsula. nihr. 
ac. uk/). A former trial participant, who expressed an 
interest in supporting our research and will be involved 
in the further dissemination of results, has co-written a 
summary sheet explaining our results in lay terms which 
has been sent to consenting former trial participants.
results
Participant flow
Participant flow through the trial is summarised in 
figure 1.
We randomised 68 participants into the trial between 
October 2015 and September 2016: 34 (50%) to each trial 
arm. One hundred and forty-six potential participants 
gave permission for study researcher contact (‘opted 
in’). We excluded 55/140 (39.3%) of those who could be 
contacted for telephone screen (24 did not meet inclusion 
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criteria; 26 declined to participate; 5 were unable to 
arrange a baseline assessment) and 17/85 (20%) of those 
who attended baseline interview (15 did not meet inclu-
sion criteria; 2 declined to participate). We randomised 
68/146 (46.6%) of those who opted into the study. The 
690 study invitations sent to potentially eligible patients 
identified via GP record search resulted in 35 participants 
randomised into the trial, a rate of 5.1% (95% CI 3.4% to 
6.6%), with an additional 33 participants recruited from 
alternative sources such as advertising.
From January 2016 to January 2017, we collected 
4-month follow-up data from 64/68 (94%) participants 
(95% CI 88.3% to 99.7%): 33/34 (97%) in the interven-
tion arm and 31/34 (91%) in the control arm. In the 
intervention arm, one participant could not be contacted 
for follow-up; in the control arm, two participants could 
not be contacted for follow-up and one withdrew on the 
basis that they had not received active treatment. An 
additional control participant, after attending follow-up, 
revoked consent for his data to be included in the trial. 
Thus, while this participant is included within the partic-
ipant flow figures, his data have not been included in the 
analysis of baseline characteristics or outcomes.
baseline data
Baseline characteristics are summarised in table 1.
receipt of Morita therapy
No participant in the intervention group declined to 
start Morita Therapy and 24/34 (70.6%) adhered to a 
per-protocol minimum (at least five sessions). The mean 
number of sessions attended for all participants was 7.7 
(range 1–14; SD 4.0); the mean number attended for 
those who did and did not adhere to the minimum dose 
Figure 1 Consolidated Standards of Reporting Trials diagram. TAU, treatment as ususal.
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Table 1 Participant baseline characteristics
Intervention (n=34) Control (n=33*) Total (n=67)
Gender
  Female 22 (64.7) 19 (57.6) 41 (61.2)
Age (years)
  Mean (SD) 49.8 (14.8) 48.6 (15.9) 49.2 (15.2)
Ethic origin
  White British 31 (91.2) 30 (90.9) 61 (91.0)
  White other 2 (5.9) 0 (0.0) 2 (3.0)
  Mixed other 0 (0.0) 2 (6.1) 2 (3.0)
  Asian Indian 0 (0.0) 1 (3.0) 1 (1.5)
  Asian other 1 (2.9) 0 (0.0) 1 (1.5)
Education
  No qualifications 3 (8.8) 2 (6.1) 5 (7.5)
  GCSE or O Level 7 (20.6) 6 (18.2) 13 (19.4)
  Post GCSE or O Level 7 (20.6) 8 (24.2) 15 (22.4)
  Undergraduate degree 9 (26.5) 10 (30.3) 19 (28.4)
  Postgraduate qualification or higher 8 (23.5) 7 (21.2) 15 (22.4)
Marital status
  Married or cohabiting 23 (67.6) 16 (48.5) 39 (58.2)
Number of children
  Mean (SD) 1 (1) 1 (1) 1 (1)
History of depression
  One or more previous episodes 29 (85.3) 25 (75.8) 54 (80.6)
  Age of onset (mean (SD)) 28.9 (17.8) 25.2 (17.4) 27.1 (17.6)
  Duration of current episode in months (mean (SD)) 13.1 (12.8) 30.3 (43.8) 21.3 (32.4)
PHQ-9 (depression) score
  Mean (SD) 17.4 (4.7) 16.1 (4.5) 16.8 (4.6)
GAD-7 (anxiety) score
  Mean (SD) 13.3 (4.8) 12.2 (4.0) 12.7 (4.4)
Secondary SCID diagnoses (current)
  Any anxiety disorder 21 (61.8) 28 (84.8) 49 (73.1)
  Generalised anxiety disorder 13 (38.2) 17 (51.5) 30 (44.8)
  Social phobia 5 (14.7) 11 (33.3) 16 (23.9)
  Panic disorder with agoraphobia 6 (17.6) 8 (24.2) 14 (20.9)
  Panic disorder without agoraphobia 7 (20.6) 3 (12.6) 10 (14.9)
  Post-traumatic stress disorder 3 (8.8) 7 (21.2) 10 (14.9)
  Obsessive compulsive disorder 2 (5.9) 5 (15.2) 7 (10.4)
  Specific phobia 1 (2.9) 4 (12.1) 5 (7.5)
  Agoraphobia without panic disorder 1 (2.9) 1 (3.0) 2 (3.0)
Antidepressant treatment
  Currently prescribed antidepressants 20 (58.8) 20 (60.6) 40 (59.7)
Previous psychotherapy/counselling (at least one course of)
  Any psychotherapy (not including counselling) 23 (67.6) 26 (78.8) 49 (73.1)
  Cognitive behavioural therapy 20 (58.8) 21 (63.6) 41 (61.2)
  Mindfulness-based cognitive therapy 8 (23.5) 6 (18.2) 14 (20.9)
  Behavioural activation 1 (2.9) 3 (9.1) 4 (6.0)
Continued
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was 9.8 (range 5–14; SD 2.5) and 2.6 (range 1–4; SD 1.0), 
respectively.
Outcomes and estimation
The SD of the outcomes at baseline and follow-up by trial 
arm, with 95% CI, are reported in table 2. At follow-up, the 
pooled SD around the mean PHQ-9 score (the primary 
outcome in any definitive trial) was 6.4% (95% CI 5.5% 
to 7.8%). The correlations between baseline and 4-month 
scores by trial arm, with 95% CI, are reported in table 3.
Outcomes in the intervention and control arms at 
baseline and follow-up, with observed between-group 
differences in changes from baseline to follow-up (with 
95% CI), are summarised in table 2. Depressive symptoms 
reduced from baseline to follow-up by an average of 9 
PHQ-9 points in the intervention group and an average 
of 3.5 PHQ-9 points in the control group.
Proportions of recovery and response on the PHQ-9 
(depressive symptoms) and GAD-7 (anxiety symptoms) 
by trial arm are summarised in table 4. At follow-up, 
22/33 participants in the intervention group (66.7%) 
scored below the threshold for moderate depression 
(PHQ-9 <10) with 9/30 controls (30.0%) similarly recov-
ering. Depressive symptoms reduced by ≥50% from 
baseline to follow-up for 22/33 participants in the inter-
vention group (66.7%) and 4/30 controls (13.3%).
service use
Participants’ use of health services (in addition to Morita 
Therapy) since baseline assessment is presented in table 5. 
These data were collected in order to characterise TAU 
in preparation for costing a large-scale trial. Service use 
was comparable across the two arms with the exception 
of psychological therapy and counselling, which were 
proscribed in the Morita Therapy arm (0% in the Morita 
Therapy arm; 26% (n=8) in TAU). Compared with base-
line assessment, antidepressant medication use reduced 
in both groups (58.8% (20/34) to 43.8% (14/32) and 
60.6% (20/33) to 45.2% (14/31) in the intervention and 
control groups, respectively).
DIsCussIOn
In this pilot RCT we have demonstrated that it is possible 
to recruit UK-based people with depression into a trial of 
Morita Therapy, and to retain them at 4-month follow-up 
at a rate which is equivalent to or exceeds that found in 
other trials in the field.22 48 50 51 Participants’ adherence 
to the minimum dose of Morita Therapy was on a par 
with other psychological therapies in similar trials.22 
Furthermore, depressive symptoms reduced from base-
line to follow-up by an average of 9 PHQ-9 points in 
the intervention group and 3.5 points in the control 
group: a between-group difference exceeding the PHQ-9 
minimum clinically important difference (MCID).52 Rates 
of recovery and response to Morita Therapy (66.7%) were 
at least as good as those achieved by leading evidence-
based psychological therapies.14 15 17–23
strengths and limitations
A key strength of this trial is that it represents the first 
study of Morita Therapy in the UK and the first RCT of 
Morita Therapy for depression within English-speaking 
countries. While the findings are consistent with 
previous studies which suggest possible benefits of Morita 
Therapy32 38 53 (Minami, M. 2011), this study provides 
a valuable contribution in terms of applying Morita 
Therapy to a UK population, and by employing a rigorous 
methodology in preparation for a fully powered trial. The 
methods used were suitable for a feasibility study: the study 
purpose and research questions accorded with the NIHR 
Evaluation Trials and Studies’ definition of a feasibility 
study,54 endorsed by Arain et al;55 the trial was designed 
to address key uncertainties associated with a large-scale 
trial; criteria for success were specified a priori.39
Due to resource limitations, the study researchers 
were not blinded to group allocation. While baseline 
and follow-up data were self-reported, and all research 
measures were applied equally to both groups, it is possible 
that this introduced detection bias into the study56 57 and 
blinding of study researchers would be ensured in any 
future definitive trial.
Implications and future research
We can now estimate the parameters necessary in order to 
design a fully powered trial based on the 95% CIs around 
our current data: we estimate that (1) The randomisa-
tion rate (as percentage of patients invited via GP record 
searches alone) would be between 3.4% and 6.6%. (2) 
Intervention (n=34) Control (n=33*) Total (n=67)
  Eye movement desensitisation and reprocessing 2 (5.9) 2 (6.1) 4 (6.0)
  Counselling 15 (44.1) 14 (42.4) 29 (43.3)
  Other psychotherapy 9 (26.5) 10 (30.3) 19 (28.4)
Notes: data are number (%) unless stated otherwise.
*Thirty-four participants were randomised into the control arm, with 33 participants’ characteristics included due to 1 participant revoking 
consent to include data.
Percentages may not always total 100 due to rounding.
GAD-7, Generalised Anxiety Disorder Questionnaire 7; SCID, Structured Clinical Interview for Diagnostic and Statistical Manual of Mental 
Disorders IV-TR (text revision) Axis Disorders, Clinical Trials Version; PHQ-9, Patient Health Questionnaire 9.
Table 1 Continued 
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The retention rate would be between 88.3% and 99.7%. 
(3) The pooled SD on the PHQ-9 (the primary outcome 
measure in a definitive trial) score at follow-up would be 
between 5.5 and 7.8. Using our pilot trial data alongside 
the most conservative estimate of the between-group 
difference based on the published PHQ-9 MCID (2.59),52 
we also estimate that 133 participants per group would 
be required to provide 90% power based on a two-sided 
5% significance level and allowing for 20% attrition. 
Our previous experience leads us to assert that we could 
reasonably expect to recruit such numbers into a future 
trial.
We specified two criteria for success39 for proceeding 
to a fully powered trial. Our pilot trial attrition rate of 
6% fulfils the specified standard (no higher than 20%), 
as does the treatment adherence rate of 70.6% (at 
least 65%). While the recruitment rate from GP record 
searches alone (5.1%) was lower than anticipated, this 
is slightly higher than that found in other trials in the 
field.50 51 To recruit 266 participants into a fully powered 
trial, based on our pilot data 51 average-sized general 
practices would need to participate in record searches. 
This could be achieved in a similar time frame to the 
pilot trial by conducting the trial over three sites (as 
opposed to one site) and with an increased workforce 
to recruit participants. Recruitment might also be maxi-
mised by identifying additional participants through 
advertising and using research registers (as per our 
Table 3 Correlation between participant scores at baseline and 4 months
Association Participants n Spearman’s ρ
95% CI around 
Spearman's ρ 
PHQ-9 at baseline and 4 months All 63 0.42 0.19 to 0.61
Intervention 33 0.37 0.04 to 0.64
Control 30 0.71 0.47 to 0.85
GAD-7 at baseline and 4 months All 62 0.40 0.17 to 0.59
Intervention 32 0.40 0.07 to 0.66
Control 30 0.51 0.18 to 0.73
WSAS at baseline and 4 months All 62 0.52 0.31 to 0.68
Intervention 32 0.45 0.12 to 0.69
Control 30 0.76 0.55 to 0.88
MASA at baseline and 4 months All 62 0.58 0.39 to 0.73
Intervention 32 0.45 0.12 to 0.69
Control 30 0.73 0.50 to 0.86
SF-36 PCS at baseline and 4 months All 63 0.68 0.52 to 0.80
Intervention 33 0.78 0.59 to 0.88
Control 30 0.58 0.27 to 0.78
SF-36 MCS at baseline and 4 months All 63 0.42 0.20 to 0.61
Intervention 33 0.43 0.10 to 0.67
Control 30 0.39 0.04 to 0.66
GAD-7, Generalised Anxiety Disorder Questionnaire 7; MASA, Morita Attitudinal Scale for Arugamama; MCS, Mental Component Score; PCS, 
Physical Component Score; PHQ-9, Patient Health Questionnaire 9; SF-36, Short Form 36 Health Survey Questionnaire; WSAS, Work and 
Social Adjustment Scale.
Table 4 Proportions of recovery and response at 4-month follow-up
Outcome measure Participants n
Recovery Response n (%) either showing 50% 
reduction or scoring <10 at 
follow-up
n (%) scoring <10 at 
follow-up
n (%) showing 50% 
reduction
PHQ-9 All 63 31 (49.2) 26 (41.3) 32 (50.8)
Intervention 33 22 (66.7) 22 (66.7) 23 (69.7)
Control 30 9 (30.0) 4 (13.3) 9 (30.0)
GAD-7 All 62 40 (64.5) 27 (43.5) 40 (64.5)
Intervention 32 24 (75.0) 17 (53.1) 24 (75.0)
Control 30 16 (53.3) 10 (33.3) 16 (53.3)
GAD-7, Generalised Anxiety Disorder Questionnaire 7; PHQ-9, Patient Health Questionnaire 9.
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current study) and by modifying the pilot trial protocol 
to include measures known to improve recruitment 
rates, such as telephone reminders to non-responding 
patients invited via GP record search.58–60 We there-
fore anticipate that a sufficient number of participants 
to populate a fully powered trial can be recruited, 
although with additional procedures, and conclude 
that a fully powered trial is feasible with minor modi-
fications to the pilot trial protocol in relation to our 
recruitment activities.
Table 5 Service use at 4-month follow-up
Service Participants n %
Number of contacts
Duration of contacts 
(minutes)
Mean SD Mean SD
Antidepressant medication 
(continuing at follow-up)
Morita Therapy (n=32) 14 43.8 - - - -
TAU (n=31) 14 45.2 - - - -
Psychological therapy Morita Therapy (n=32) 0 0.0 – – – – 
TAU (n=31) 5 16.1 5.4 4.4 68.0 47.6
Counselling Morita Therapy (n=32) 0 0.0 – – – – 
TAU (n=31) 3 9.7 6.3 2.1 60.0 0.0
Hospital admission Morita Therapy (n=33) 2 6.1 1.5 0.7 - -
TAU (n=31) 1 3.2 1.0 0.0 - -
Hospital outpatient appointment Morita Therapy (n=32) 9 28.1 2.1 1.5 - -
TAU (n=31) 9 29.0 2.1 3.0 - -
A&E attendance Morita Therapy (n=32) 3 9.4 1.0 0.0 - -
TAU (n=31) 3 9.7 1.3 0.6 - -
GP appointment Morita Therapy (n=32) 20 62.5 4.8 4.0 12.0 2.4
TAU (n=31) 17 54.8 2.5 2.0 12.8 6.2
GP home visit Morita Therapy (n=32) 2 6.3 1.0 0.0 12.5 3.5
TAU (n=31) 0 0.0 – – – – 
GP telephone contact Morita Therapy (n=32) 10 31.3 3.5 5.0 6.9 4.5
TAU (n=31) 5 16.1 2.4 1.7 5.0 3.1
Practice nurse Morita Therapy (n=32) 7 21.9 3.6 5.3 9.3 6.7
TAU (n=31) 10 32.3 1.6 1.1 12.0 5.8
Psychiatrist Morita Therapy (n=32) 0 0.0 – – – – 
TAU (n=31) 1 3.2 12 0.0 50.0 0.0
Occupational therapist Morita Therapy (n=32) 2 6.3 2.5 0.7 35.0 35.4
TAU (n=31) 1 3.2 5.0 0.0 45.0 0.0
Social worker Morita Therapy (n=32) 1 3.1 5.0 0.0 60.0 0.0
TAU (n=31) 0 0.0 – – – – 
Advice service Morita Therapy (n=32) 2 6.3 1.0 0.0 75.0 21.2
TAU (n=31) 1 3.2 1.0 0.0 60.0 0.0
Helpline Morita Therapy (n=32) 1 3.1 1.0 0.0 60.0 0.0
TAU (n=31) 2 6.5 25.0 0.0 30.0 0.0
Chiropractor Morita Therapy (n=32) 5 15.6 3.8 3.0 29.0 17.5
TAU (n=31) 3 9.7 2.0 1.7 41.7 10.4
Acupuncture Morita Therapy (n=32) 1 3.1 1.0 0.0 30.0 0.0
TAU (n=31) 1 3.2 9.0 0.0 60.0 0.0
Physiotherapist Morita Therapy (n=32) 1 3.1 3.0 0.0 60.0 0.0
TAU (n=31) 1 3.2 4.0 0.0 60.0 0.0
Mental Health support worker Morita Therapy (n=32) 1 3.1 1.0 0.0 60.0 0.0
TAU (n=31) 1 3.2 6.0 0.0 60.0 0.0
A&E, accident and emergency; GP, general practitioner; TAU, treatment as usual.
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The level of participant adherence to Morita Therapy 
suggests that it is as acceptable to participants as other 
psychological treatments.22 While it is not the purpose of 
this paper to assess the effectiveness of Morita Therapy 
and the study was not powered to enable inferential 
statements to be made, our findings also suggest prom-
ising possible effects of Morita Therapy plus TAU versus 
TAU alone.61 The observed between-group difference in 
reduction in depressive symptoms (PHQ-9) from baseline 
to follow-up, and indeed the lower margin of error on this 
figure, exceeds the PHQ-9 MCID. Furthermore, the rates 
of recovery and treatment response found in this study 
are comparable to or exceed those found for current 
NICE-recommended treatments for depression.14 15 17–23 
While these findings suggest that Morita Therapy may be 
equivalent in effectiveness to other psychological thera-
pies, supporting the potential value of Morita Therapy 
as a treatment for depression, our qualitative and mixed-
methods findings (reported elsewhere) provide early 
indications of which patients might benefit most from 
Morita Therapy, which will be incorporated into a process 
evaluation in a fully powered trial.62
In line with this, given that treatment effective-
ness varies at an individual if not population level, it is 
argued that research should focus on matching patient 
characteristics to treatment type.63–66 In order to facili-
tate such work, it makes sense to test treatments which 
are qualitatively distinct from current options. Given 
the contrast between Morita Therapy and established 
Western approaches,28 Morita Therapy may prove a valu-
able addition to current treatment options by providing 
a meaningful alternative which may be particularly suited 
to patients for whom current treatments are not suitable. 
As such, Morita Therapy may facilitate both true patient 
choice (as enshrined in the forthcoming NICE guidelines 
for depression67) and the future ‘matching’ of patients 
to treatments, and potentially provide patients for whom 
current NICE-recommended therapies have failed a qual-
itatively different approach towards mental health.
COnClusIOns
We have determined that it is feasible to conduct a large-
scale trial of Morita Therapy with minor modifications to 
the pilot trial protocol in order to maximise recruitment. 
Our findings indicate that Morita Therapy shows promise 
in the treatment of depression, supporting the potential 
of Morita Therapy to provide patients in the UK with a 
distinct and meaningful alternative to current treatment 
options.
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